Stevens-johnson syndrome and toxic epidermal necrolysis (SJS/TEN): Could retinoids play a causative role?

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 133-143

  Mawson, Anthony R ^a   Eriator, Ike ^b   Karre, Sridhar ^b  

^a JACKSON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

References; Retinoids; Stevens johnson syndrome

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; CORTICOSTEROID; GRANULYSIN; INSULIN; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; RETINOID; ANTIINFECTIVE AGENT; GNLY PROTEIN, HUMAN; RETINOL; T LYMPHOCYTE ANTIGEN;

ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; CHOLESTASIS; DIETARY INTAKE; INSULIN RESISTANCE; LIPID STORAGE; LIVER DYSFUNCTION; METABOLISM; OBSTRUCTIVE JAUNDICE; PATHOGENESIS; PHLEBOTOMY; PLASMAPHERESIS; RETINOL INTOXICATION; REVIEW; SIGNAL TRANSDUCTION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EPIDERMIS; HUMAN; KERATINOCYTE; LIVER; PATHOPHYSIOLOGY; SKIN; STEVENS-JOHNSON SYNDROME;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CHOLESTASIS; EPIDERMIS; HUMANS; HYPERVITAMINOSIS A; KERATINOCYTES; LIVER; RETINOIDS; SKIN; STEVENS-JOHNSON SYNDROME; VITAMIN A;

EID: 84920992382     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.891043     Document Type: Review

References (94)

1. Stevens AM, Johnson FC: A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child, 1922; 24: 526-53
2. Lyell A: Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol, 1956; 68: 355-61
3. Pereira FA, Mudgil AV, Rosmarin DM: Toxic epidermal necrolysis. J Am Acad Dermatol, 2007; 56(2): 181-200
4. Abe R, Shimizu T, Shibaki A et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble fas ligand. Am J Pathol, 2003; 162: 1515-20
5. Farthing P, Bagan J, Scully C: Mucosal disease series. Number IV. Erythema multiforme. Oral Dis, 2005; 11(5): 261-67
6. Rehmus WE: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Merck Manuals, October 2009; http://www.merck.com/mmpe/sec10?ch117/ch117i.html
7. Roujeau JC, Kelly JP, Naldi L et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med, 1995; 333: 1600-7
8. Fritch PO, Sidoroff A: Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol, 2000; 1: 349-60
9. Majumdar S, Mockenhaupt M, Roujeau JC, Townshend A: Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev, 2002; 4: CD001435
10. Leone R, Venegoni M, Motola D et al: Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluroquinolone consumption data from three Italian regions. Drug Saf, 2003; 26: 109-20
11. Mockenhaupt M, Viboud C, Dunant A et al: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol, 2008; 128: 53-44
12. Struck MF, Hilbert P, Mockenhaupt M et al: Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med, 2010; 36: 22-32
13. Chopra A, Drage LA, Hanson EM, Touchet NL: Stevens-Johnson syndrome after immunization with smallpox, anthrax and tetanus vaccines. Mayo Clinic Proc, 2004; 79: 1193-96
14. Chen KT, Two SJ, Chang HJ, Lin RS: Outbreak of Stevens-Johnson syndrome?Toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health, 2003; 93: 489-92
15. Ganguly J: The Biochemistry of Vitamin A. Boca Raton, FL: CRC Press, 1989
16. Hoffman C, Eichele G: Retinoids in development. In Sporn MB, Roberts AB, Goodman DS (eds.), The Retinoids: Biology, Chemistry, and Medicine. New York: Raven Press, 1994, 387-441
17. Litwack G (ed.), Vitamin A: Vitamins and Hormones, Vol. 75. San Diego, CA: Elsevier Academic Press, 2007
18. Theodosiou M, Laudet V, Schubert M: From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci, 2010; 67: 1423-45
19. Gambone CJ, Hutcheson JM, Gabriel JL et al: Unique property of some synthetic retinoids: Activation of the aryl hydrocarbon receptor pathway. Mol Pharmacol, 2002; 61: 334-42
20. Berry DC, Jin H, Majumdar A, Noy N: Signaling by vitamin A and retinolbinding protein regulates gene expression to inhibit insulin responses. Proc Nat Acad Sci USA, 2011; 108(11): 4340-45
21. Yang Q, Graham TE, Mody N et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005; 436(7049): 356-62
22. Blomhoff R, Blomhoff HK: Overview of retinoid metabolism and function. J Neurobiol, 2006; 66: 606-30
23. Penniston KL, Tanumihardjo SA: The acute and chronic toxic effects of vitamin A. Am J Clin Nutr, 2006; 83: 191-201
24. Miller RK, Hendricks AG, Mills JL et al: Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol, 1998; 12: 75-88
25. Olson JA: Vitamin A. In Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition, edition 7. Washington, DC: International Life Sciences Institute Press; 2001: 109-19
26. Leo MA, Lieber CS: Hypervitaminosis A: A liver lover’s lament. Hepatology, 1988; 8: 412-17
27. Mezey E: Liver disease and protein needs. Annu Rev Nutr, 1982; 2: 21-50
28. Morelli MS, O’Brien FX: Stevens-Johnson Syndrome and cholestatic hepatitis. Dis Dis Sci, 2001; 46: 2385-88
29. Rodahl K, Moore T: The vitamin A content and toxicity of bear and seal liver. Biochem J, 1943; 37: 166-68
30. McIvor A: Fatal toxic epidermal necrolysis associated with etretinate. Br Med J, 1992; 304: 548
31. Ramsay B, Bloxham C, Eldred A et al: Blistering, erosions and scarring in a patient on etretinate. Br J Dermatol, 1989; 121: 397-400
32. Kharfi M, Khaled A, Ammar D et al: Generalized peeling skin syndrome: Case report and review of the literature. Dermatol Online J, 2010; 16(3): 1
33. Mevorah B, Salomon D, Siegenthaler G et al: Ichthyosiform dermatosis with superficial blister formation and peeling: evidence for a desmosomal anomaly and altered epidermal vitamin A metabolism. J Am Acad Dermatol, 1996; 34: 379-85
34. Kim BH, Lee YS, Kang KS: The mechanism of retinol-induced irritation and its application to anti-irritant development. Toxicol Lett, 2003; 15: 65-73
35. Kumar G, Fadel HJ, Beckman TJ: 36-year-old man with productive cough and diffuse rash. Mayo Clinic Proc, 2006; 81: 945-48
36. Ward KE, Archambault R, Mersfelder TL: Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. Am J Health Syst Pharm, 2010; 67: 206-13
37. Rzany B, Correia O, Kelly JP et al: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet, 1999; 353: 2190-94
38. Nau H, Tzimas G, Mondry M et al: Antiepileptic drugs alter endogenous retinoid concentrations: a possible mechanism of teratogenesis of anticonvulsant therapy. Life Sci, 1995; 57: 53-60
39. Altuntaş Y, Ozturk B, Erdem L et al: Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions: case report. South Med J, 2003; 96: 201-3
40. Slatore CG, Tilles SA: Sulfonamide hypersensitivity. Immunol Allergy Clin North Am, 2004; 24(3): 477-90, vii
41. Harber LC: Abnormal response to ultraviolet radiation: drug-induced photosensitivity. Cha42. Blue M, Bozdech JM. Drug-induced liver injury. In Achkar E, Farmer RG, Fleshler B (eds.), Clinical Gastroenterology. 2nd edition. Philadelphia: Lea & Febiger, 1992; 574-80
42. Hellmann-Regen J, Herzog I, Fischer N et al: Do tetracyclines and erythromycin exert anti-acne effects by inhibition of P450-mediated degradation of retinoic acid? Exp Dermatol, 2014; 23(4): 290-93
43. Moore T: Vitamin A. Cambridge: Cambridge University Press, 1957
44. Felix-Getzik E, Sylvia LM: Vancomycin-induced leukocytoclastic vasculitis. Pharmacotherapy, 2009; 29: 846-51
45. Marill J, Idres N, Capron CC et al: Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab, 2003; 4: 1-10
46. Tiboni GM, Marotta F, Carletti E: Fluconazole alters CYP26 gene expression in mouse embryos. Reprod Toxicol, 2009; 27(2): 199-202
47. Napoli JL: Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Molec Biol, 2000; 63: 139-88
48. Marikar Y, Wang Z, Duell EA et al: Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells. J Invest Dermatol, 1998; 111: 434-39
49. Nanau RM, Neuman MG: Ibuprofen-induced hypersensitivity syndrome. Transl Res, 2010; 155: 275-93
50. Drazen JM: Leukotrienes as mediators of airway obstruction. Am J Respir Care Med, 1998; 108: 47-51
51. Lam BK, Penrose JF, Freeman GJ, Austen KF: Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci USA, 1994; 91: 4275-79
52. Kligman LH, Murpy GF: Topical tretinoin increases dermal mast cells, induces epidermal mast cell growth factor (c-kit ligand) and modulates its distribution in hairless mice. Arch Dermatol Res, 1996; 288: 537-42
53. Babina M, Mammeri K, Henz BM: Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion-evidence of retinoid signaling pathways in the mast cell lineage. J Leukoc Biol, 2001; 69: 361-72
54. Abe M, Shibata, Saruwater S et al: cDNA cloning and expression of rat leukotriene C4 synthase: elevated expression in rat basophilic leukemia-1 cells after treatment with retinoic acid. Prostaglandins Leukot Essent Fatty Acids, 2002; 67: 319-26
55. Hamasaki Y, Abe M, Matsumoto S et al: Inhibition by dexamethasone of retinoic acid-induced enhancement of leukotriene C4 synthesis in rat basophilic leukemia-1 cells. Am J Resp Cell Mol Biol, 1994; 11: 49-56
56. Graves PR, Kwiek JJ, Fadden P et al: Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol, 2002; 62: 1364-72
57. Rynes RI: Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol, 1997; 36: 799-805
58. Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother, 1993; 27: 337-43
59. Moffa DJ, Lotspeich FJ, Krause RF: Preparation and properties of retinal-oxidizing enzyme from rat intestinal mucosa. J Biol Chem, 1970; 245: 439-47
60. Mawson AR, Onor GI: Gout and vitamin A intoxication: Is there a connection? Semin Arthritis Rheum, 1991; 20: 297-304
61. Taibi G, Paganini A, Geuli MC et al: Milk xanthine oxidase catalyzes the synthesis of retinoic acid. J Enzyme Inhib, 2001; 16(3): 275-85
62. Rees F, Hui M, Doherty M: Optimizing current treatment of gout. Nature Rev Rheumatol, 2014; 10: 271-83
63. Patterson R, Miller M, Kaplan M et al: Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy, 1994; 73: 27-34
64. Keleman JJ, Cioffi WG, McManus WF et al: Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg, 1995; 180: 273-78
65. Clark I, Colburn RW: A relationship between vitamin A metabolism and cortisone. Endocrinology, 1955; 56: 232-38
66. Georgieff MK, Radmer WJ, Sowell AL et al: The effects of glucocorticosteroids on serum, liver, and lung vitamin A and retinyl ester concentrations. J Pediatr Gastroenterol Nutr, 1991; 13: 376-82
67. Ghislain P-D, Roujeau J-C: Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online, 2002; 8(1): 5
68. Saitoh A, Kawanabe T, Weidong H et al: Selective upregulation of fibroblast fas ligand expression, and prolongation of fas/fas ligand-mediated skin allograft survival, by retinoic acid: the skin as a retinoid-inducible immune privileged site. J Invest Derm, 2000; 115: 154-61
69. French LE, Tschopp J: Protein-based therapeutic approaches targeting death receptors. Cell Death and Differ, 2003; 10: 117-23
70. Abe R: Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J Dermatol Sci, 2008; 52: 151-59
71. Chung WH, Hung SI, Yang JY et al: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med, 2008; 14(12): 1343-50
72. Noy N: Between death and survival: retinoic acid in regulation of apoptosis. Annu Rev Nutr, 2010; 30: 201-17
73. Schmidt-Mende J, Gogvadze V, Hellstrom-Lindberg E, Zhivotovsky B: Early mitochondrial alterations in ATRA-induced cell death. Cell death and differentiation, 2006; 13: 119-28
74. Mrass P, Rendl M, Mildner M et al: Retinoic acid increases the expression of p53 and proapoptopic caspases and sensitizes ketatinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res, 2004; 64: 6542-48
75. Islam TC, Skarin T, Sumitran S, Toftgard R: Retinoids induce apoptosis in cultured keratinocytes. Br J Dermatol, 2000; 143: 709-19
76. Schug TT, Berry DC, Shaw NS et al: Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell, 2007; 129: 723-33
77. Krasinski SD, Kohn JS, Schaefer EJ, Russell RM: Post prandial plasma retinyl ester response is greater in older subjects compared with younger subjects. J Clin Invest, 1990; 85: 883-92
78. Abe R, Yoshioka N, Murata J et al: Granulysin as a marker for early diagnosis of the Stevens-Johnson Syndrome. Ann Intern Med, 2009; 151: 514-15
79. Tewary P, Yang D, de la Rosa G et al: Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. Blood, 2010; 116(18): 3465-74
80. Zitvogel L, Kroemer G: The multifaceted granulysin. Blood, 2010; 116(18): 3379-80
81. Kaspar AA, Okadas S, Kumar J et al: A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol, 2001; 167: 350-56
82. Zhang H, Zhong C, Shi I et al: Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochrondria through processing of bid leading to Necroptosis. J Immunol, 2009; 182(11): 6993-7000
83. Pardo J, Perez-Galan P, Gamen S et al: A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J Immunol, 2001; 167(3): 1222-29
84. Dingle T, Lucy JA: Studies on the mode of action of excess vitamin A. The effect of vitamin A on the stability of the erythrocyte membrane. J Biochem, 1962; 84: 611-21
85. Gery I: Inhibition of DNA and RNA synthesis in lymphocyte cultures by rod outer segments and its counteraction by vitamin E and other antioxidants. Invest Ophthalmol Vis Sci, 1980; 19: 751-59
86. Urano S, Inomori Y, Sugawara T et al: Vitamin E: inhibition of retinol-induced hemolysis and membrane-stabilizing behavior. J Biol Chem, 1992; 267: 18365-70
87. Hogg AE, Bowick GC, Herzog NK et al: Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1. J Leukoc Biol, 2009; 86(5): 1191-203
88. DePaolo RW, Abadie V, Tang F et al: Co-adjuvant effects of retinoic acid and IL-15 promote inflammatory immune responses to dietary antigens. Nature, 2011; 471: 220-24
89. Arranz E, Garrote JA: IL-15 modulates the effect of retinoic acid, promoting inflammation rather than oral tolerance to dietary antigens. Expert Rev Gastroenterol Hepatol, 2011; 5(3): 315-17
90. Reddy D, Siegel CA, Sands BE, Kane S: Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol, 2006; 101(7): 1569-73
91. Crockett SD, Porter CQ, Martin CF et al: Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol, 2010; 105(9): 1986-93
92. Gomes ER, Demoly P: Epidemiology of hypersensitivity drug reactions. Curr Opin Clin Immunol, 2005; 5: 309-16
93. Ihara H, Shino Y, Hashizume N et al: Decline in plasma retinol in unconjugated hyperbilirubinemia treated with bilirubin adsorption using an anionexchange resin. J Nutr Sci Vitaminol (Tokyo), 1998; 44: 329-36
94. Egan CA, Grant WJ, Morris SE et al: Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol, 1999; 40: 458-61